A dataset for the analysis of antibody response to glycan alpha-Gal in individuals with immune-mediated disorders

Fuente, José de la; Urra, José Miguel; Contreras, Marinela; Pacheco, Iván; Ferreras, Elisa; Doncel‐Pérez, Ernesto; Mera, Isabel G. Fernández de; Villar, Margarita; Cabrera, Carmen; Hernando, César Gómez; Vargas-Baquero, Eduardo; García, Javier Blanco; Gómez, José Manuel López; Galán, Alberto Velayos; Brito, Francisco; Torrijos, Elisa Gómez; Cabezas‐Cruz, Alejandro; Gortázar, Christian

doi:10.12688/f1000research.27495.1

Cited by 6 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective case-control study was conducted in patients suffering from COVID-19 and healthy controls sampled at the University General Hospital of Ciudad Real (HGUCR), Spain (28,29). Blood samples from control individuals were collected prior to the COVID-19 pandemic in April 2019.…”

Section: Samples From Healthy Individuals and Covid-19 Patientsmentioning

confidence: 99%

Characterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology

et al. 2021

Self Cite

View full text Add to dashboard Cite

The COVID-19 pandemic caused by SARS-CoV-2 challenges the understanding of factors affecting disease progression and severity. The identification of prognostic biomarkers and physiological processes associated with disease symptoms is relevant for the development of new diagnostic and therapeutic interventions to contribute to the control of this pandemic. To address this challenge, in this study, we used a quantitative proteomics together with multiple data analysis algorithms to characterize serum protein profiles in five cohorts from healthy to SARS-CoV-2-infected recovered (hospital discharge), nonsevere (hospitalized), and severe [at the intensive care unit (ICU)] cases with increasing systemic inflammation in comparison with healthy individuals sampled prior to the COVID-19 pandemic. The results showed significantly dysregulated proteins and associated biological processes and disorders associated to COVID-19. These results corroborated previous findings in COVID-19 studies and highlighted how the representation of dysregulated serum proteins and associated BPs increases with COVID-19 disease symptomatology from asymptomatic to severe cases. The analysis was then focused on novel disease processes and biomarkers that were correlated with disease symptomatology. To contribute to translational medicine, results corroborated the predictive value of selected immune-related biomarkers for disease recovery [Selenoprotein P (SELENOP) and Serum paraoxonase/arylesterase 1 (PON1)], severity [Carboxypeptidase B2 (CBP2)], and symptomatology [Pregnancy zone protein (PZP)] using protein-specific ELISA tests. Our results contributed to the characterization of SARS-CoV-2–host molecular interactions with potential contributions to the monitoring and control of this pandemic by using immune-related biomarkers associated with disease symptomatology.

show abstract

Section: Samples From Healthy Individuals and Covid-19 Patientsmentioning

confidence: 99%

Characterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Essential methods used for the generation of the dataset ( de la Fuente et al ., 2020 ) were described in Urra et al . (2021) with additional information in Pacheco et al .…”

Section: Methodsmentioning

confidence: 99%

“…The dataset ( de la Fuente et al ., 2020 ) was validated in studies reported by Urra et al . (2021) , Pacheco et al .…”

Section: Methodsmentioning

confidence: 99%

“…Harvard Dataverse: A dataset for the analysis of antibody response to glycan alpha-Gal in individuals with immune-mediated disorders. https://doi.org/10.7910/DVN/RBU2VR ( de la Fuente et al ., 2020 ).…”

Section: Data Availabilitymentioning

confidence: 99%

“…This evolutionary adaptation has been associated with the protective response of anti-α-Gal IgM/IgG antibodies against pathogens containing this modification on membrane proteins ( Galili, 2019 ; Hodžić et al ., 2020a ). In contrast, the presence of α-Gal in tick salivary glycoproteins and glycolipids ( Araujo et al ., 2016 ; Cabezas-Cruz et al ., 2018 ; Chinuki et al ., 2016 ; Crispell et al ., 2019 ) and tick cement ( Villar et al ., 2020 ) induces anti-α-Gal IgE antibodies that mediate delayed anaphylaxis to mammalian meat consumption and immediate anaphylaxis to tick bites, xenotransplantation and certain drugs such as cetuximab ( Cabezas-Cruz et al ., 2019 ; Commins et al ., 2009 ; Contreras et al ., 2020 ; de la Fuente et al ., 2019a ; de la Fuente et al ., 2020 ; Fischer et al ., 2016 ; Levin et al ., 2019 ; Mateos-Hernández et al ., 2017 ; Platts-Mills et al ., 2020 ; Steinke et al ., 2015 ; van Nunen et al ., 2007 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A dataset for the analysis of antibody response to glycan alpha-Gal in individuals with immune-mediated disorders

et al. 2021

Self Cite

View full text Add to dashboard Cite

Humans evolved by losing the capacity to synthesize the glycan Galα1-3Galβ1-(3)4GlcNAc-R (α-Gal), which resulted in the development of a protective response mediated by anti-α-Gal IgM/IgG/IgA antibodies against pathogens containing this modification on membrane proteins. As an evolutionary trade-off, humans can develop the alpha-Gal syndrome (AGS), a recently diagnosed disease mediated by anti-α-Gal IgE antibodies and associated with allergic reactions to mammalian meat consumption and tick bites. However, the anti-α-Gal antibody response may be associated with other immune-mediated disorders such as those occurring in patients with COVID-19 and Guillain-Barré syndrome (GBS). Here, we provide a dataset (209 entries) on the IgE/IgM/IgG/IgA anti-α-Gal antibody response in healthy individuals and patients diagnosed with AGS, tick-borne allergies, GBS and COVID-19. The data allows correlative analyses of the anti-α-Gal antibody response with factors such as patient and clinical characteristics, record of tick bites, blood group, age and sex. These analyses could provide insights into the role of anti-α-Gal antibody response in disease symptomatology and possible protective mechanisms.

show abstract

Antibody isotype epitope mapping of SARS‐CoV‐2 Spike RBD protein: Targets for COVID‐19 symptomatology and disease control

et al. 2023

Self Cite

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) still poses a challenge for biomedicine and public health. To advance the development of effective diagnostic, prognostic, and preventive interventions, our study focused on high‐throughput antibody binding epitope mapping of the SARS‐CoV‐2 spike RBD protein by IgA, IgM and IgG antibodies in saliva and sera of different cohorts from healthy uninfected individuals to SARS‐CoV‐2‐infected unvaccinated and vaccinated asymptomatic, recovered, nonsevere, and severe patients. Identified candidate diagnostic (455‐LFRKSNLKPFERD‐467), prognostic (395‐VYADSFVIRGDEV‐407‐C‐KLH, 332‐ITNLCPFGEV‐342‐C‐KLH, 352‐AWNRKRI‐358‐C‐KLH, 524‐VCGPKKSTNLVKN‐536‐KLH), and protective (MKLLE‐487‐NCYFPLQSYGFQPTNGVG‐504‐GGGGS‐446‐GGNYNYLYRLFRKSNLKPFERD‐467) epitopes were validated with sera from prevaccine and postvaccine cohorts. The results identified neutralizing epitopes and support that antibody recognition of linear B‐cell epitopes in RBD protein is associated with antibody isotype and disease symptomatology. The findings in asymptomatic individuals suggest a role for anti‐RBD antibodies in the protective response against SARS‐CoV‐2. The possibility of translating results into diagnostic interventions for the early diagnosis of asymptomatic individuals and prognosis of disease severity provides new tools for COVID‐19 surveillance and evaluation of risks in hospitalized patients. These results, together with other approaches, may contribute to the development of new vaccines for the control of COVID‐19 and other coronavirus‐related diseases using a quantum vaccinomics approach through the combination of protective epitopes.

show abstract

A dataset for the analysis of antibody response to glycan alpha-Gal in individuals with immune-mediated disorders

Cited by 6 publications

References 39 publications

Characterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology

Characterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology

A dataset for the analysis of antibody response to glycan alpha-Gal in individuals with immune-mediated disorders

Antibody isotype epitope mapping of SARS‐CoV‐2 Spike RBD protein: Targets for COVID‐19 symptomatology and disease control

Contact Info

Product

Resources

About